

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1. (previously presented) A transgenic mouse whose genome comprises a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous gene encoding E-selectin wherein the polynucleotide encoding a soluble marker protein is inserted into a region of an E-selectin gene of a chromosomal E-selectin allele of the mouse which is between a transcription start site and a translation start site of the E-selectin gene, wherein the mouse expresses the soluble marker protein by endothelial cells and the expression is regulatable by chemical or physical stimulus, and wherein the polynucleotide comprises SEQ ID NO:11 or SEQ ID NO:12.

Claims 2-8. (cancelled).

Claim 9. (withdrawn-previously presented) A transgenic knockout mouse which is homozygous or heterozygous for a chromosomal E-selectin allele comprising a genetic construct comprising a soluble reporter transgene, said soluble reporter transgene being under the control of the promoter of the E-selectin gene of said chromosomal E-selectin allele, and said genetic construct being inserted into a region which is between a transcription start site and a translation start site of the E-selectin gene of the chromosomal E-selectin allele wherein the soluble marker protein is secreted alkaline phosphatase.

Claim 10. (canceled).

Claim 11. (withdrawn-previously presented) A transgenic mouse according to claim 9 wherein the genetic construct comprises SEQ ID NO:11 or SEQ ID NO:12.

Claim 12. (withdrawn) An isolated cell derived from the transgenic mouse according to claim 9.

Claim 13. (withdrawn) DNA having SEQ ID NO:9 or SEQ ID NO:10.

Claim 14. (withdrawn-currently amended) A method of screening for an agent having therapeutic utility, comprising:

- (a) administering the agent to a transgenic ~~mouse~~ mouse or somatic recombinant non-human animal according to claim 1
- (b) monitoring marker concentration in a body fluid of said ~~mouse~~ mouse animal, and

(c) comparing said marker concentration to the concentration of marker in an untreated transgenic ~~mouse or somatic recombinant non-human animal~~, an elevated level being indicative of the therapeutic utility of the agent.

Claim 15. (withdrawn-currently amended) A method of screening for an agent which is a modulator of E-selectin expression, comprising:

(a) administering the agent to a transgenic ~~mouse or somatic recombinant non-human animal~~ according to claim 1,

(b) monitoring marker concentration in a body fluid, and

(c) comparing said marker concentration to the concentration of marker in an untreated transgenic ~~mouse or somatic recombinant non-human animal~~, an modulated level being indicative of the capability of said agent of modulating E-selectin expression.

Claims 16-17. (canceled).

Claim 18. (withdrawn-currently amended) A method of monitoring disease progression comprising

(a) crossing a transgenic ~~mouse non-human animals~~ according to claim 1 with an animal strain used as an animal model,

(b) recovering at least one offspring, and

(c) monitoring at least one offspring for disease progression in relation to marker concentration in a body fluid.